pLV-H2B-iRFP670-p2a-mCerulean-Cdt1 (1-100)-IRES-puromycin Citations (3)

Originally described in: Non-canonical pathway for Rb inactivation and external signaling coordinate cell-cycle entry without CDK4/6 activity.
Zhang M, Kim S, Yang HW Nat Commun. 2023 Nov 29;14(1):7847. doi: 10.1038/s41467-023-43716-y. PubMed Journal

---

Articles Citing pLV-H2B-iRFP670-p2a-mCerulean-Cdt1 (1-100)-IRES-puromycin

Articles
Dual targeting of CDK4/6 and CDK7 augments tumor response and antitumor immunity in breast cancer models. Kim S, Son E, Park HR, Kim M, Yang HW. J Clin Invest. 2025 Aug 12;135(20):e188839. doi: 10.1172/JCI188839. eCollection 2025 Oct 15. PubMed
Antagonistic regulation of LINE-1/Alu elements and their repressor APOBEC3B in cellular senescence. Munot D, Lu Y, Haussmann I, Najjar G, Baur C, Singh M, Gunes C, Sauter D, Arora A. Mob DNA. 2025 Oct 21;16(1):39. doi: 10.1186/s13100-025-00378-5. PubMed
Therapeutic benefits of maintaining CDK4/6 inhibitors and incorporating CDK2 inhibitors beyond progression in breast cancer. Armand J, Kim S, Kim K, Son E, Kim M, Kalinsky K, Yang HW. Elife. 2025 Dec 29;14:RP104545. doi: 10.7554/eLife.104545. PubMed

If you have published an article using this material, please email us at to have your article added to this page.